Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 104 participants.

Also called NCT06657209

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 104 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06657209
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06657209. Randomized; no masking; primary purpose treatment. Start 2025-01-13 (actual); primary completion 2027-12-15 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide
Condition
Diabetes Mellitus, Type 2
Condition
Diabetes
Condition
Pre Diabetes
Intervention (Procedure)
Insulin resistance testing
Intervention (Procedure)
OGTT
Intervention (Procedure)
Fat biopsy
Intervention (Radiation)
DXA scan
Intervention (Procedure)
MRI
Intervention (Procedure)
1H-MRS
Intervention (Drug)
Tirzepatide
Intervention (Drug)
Pioglitazone
Lead sponsor
Stanford University (class: other)

Record details

Record id
cardio:ct-nct06657209
Content hash
bd8981757c800adbeecaa17cec9e523056fc27bed3fee75e874fd28b0a541440